Glamuzina, Emma <br/><br/>
Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.  [electronic resource] 

 -  Journal of inherited metabolic disease  Jun 2011 
 - 749-54 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article 
<br/><br/><label>ISSN: </label>1573-2665 
<br/><br/><label>Standard No.: </label>10.1007/s10545-011-9280-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Child<br/>Child, Preschool<br/>Clinical Trials as Topic--methods<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Endpoint Determination--methods<br/>Enzyme Replacement Therapy<br/>Humans<br/>Iduronate Sulfatase--therapeutic use<br/>Infant<br/>Infant, Newborn<br/>Male<br/>Mucopolysaccharidosis II--diagnosis<br/>Prognosis<br/>Research Design<br/>Retrospective Studies<br/>Treatment Outcome